I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Plasma Fractionation: Overview & Outlook

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS
Intravenous Immunoglobulin Products Gain Traction
Rising Incidence of Respiratory Diseases: Major Driver
Growing Prevalence of Bleeding Disorders Bodes Well
Rise in AATD Cases Steers Demand
Advancements in Plasma Collection Technology Favor Growth
Recombinant Technology: Key Challenge

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Plasma
Fractionation by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR

Table 2: World Historic Review for Plasma Fractionation by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 3: World 15-Year Perspective for Plasma Fractionation by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets for Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for Intravenous
Immunoglobulins by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 5: World Historic Review for Intravenous Immunoglobulins
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 6: World 15-Year Perspective for Intravenous
Immunoglobulins by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific
and Rest of World for Years 2012, 2020 & 2027

Table 7: World Current & Future Analysis for Coagulation Factor
Concentrates by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR

Table 8: World Historic Review for Coagulation Factor
Concentrates by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 9: World 15-Year Perspective for Coagulation Factor
Concentrates by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific
and Rest of World for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Albumin by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR

Table 11: World Historic Review for Albumin by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 12: World 15-Year Perspective for Albumin by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2020 & 2027

Table 13: World Current & Future Analysis for Protease
Inhibitors by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR

Table 14: World Historic Review for Protease Inhibitors by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 15: World 15-Year Perspective for Protease Inhibitors by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 16: World Current & Future Analysis for Other Products by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR

Table 17: World Historic Review for Other Products by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 18: World 15-Year Perspective for Other Products by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 19: World Current & Future Analysis for Hospitals &
Clinics by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR

Table 20: World Historic Review for Hospitals & Clinics by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 21: World 15-Year Perspective for Hospitals & Clinics by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 22: World Current & Future Analysis for Clinical Research
Laboratories by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR

Table 23: World Historic Review for Clinical Research
Laboratories by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 24: World 15-Year Perspective for Clinical Research
Laboratories by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific
and Rest of World for Years 2012, 2020 & 2027

Table 25: World Current & Future Analysis for Academic
Institutes by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR

Table 26: World Historic Review for Academic Institutes by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 27: World 15-Year Perspective for Academic Institutes by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES
Table 28: USA Current & Future Analysis for Plasma
Fractionation by Product - Intravenous Immunoglobulins,
Coagulation Factor Concentrates, Albumin, Protease Inhibitors
and Other Products - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR

Table 29: USA Historic Review for Plasma Fractionation by
Product - Intravenous Immunoglobulins, Coagulation Factor
Concentrates, Albumin, Protease Inhibitors and Other Products
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 30: USA 15-Year Perspective for Plasma Fractionation by
Product - Percentage Breakdown of Value Sales for Intravenous
Immunoglobulins, Coagulation Factor Concentrates, Albumin,
Protease Inhibitors and Other Products for the Years 2012, 2020 &
2027

Table 31: USA Current & Future Analysis for Plasma
Fractionation by End-Use - Hospitals & Clinics, Clinical
Research Laboratories and Academic Institutes - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 32: USA Historic Review for Plasma Fractionation by
End-Use - Hospitals & Clinics, Clinical Research Laboratories
and Academic Institutes Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 33: USA 15-Year Perspective for Plasma Fractionation by
End-Use - Percentage Breakdown of Value Sales for Hospitals &
Clinics, Clinical Research Laboratories and Academic Institutes
for the Years 2012, 2020 & 2027

CANADA
Table 34: Canada Current & Future Analysis for Plasma
Fractionation by Product - Intravenous Immunoglobulins,
Coagulation Factor Concentrates, Albumin, Protease Inhibitors
and Other Products - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR

Table 35: Canada Historic Review for Plasma Fractionation by
Product - Intravenous Immunoglobulins, Coagulation Factor
Concentrates, Albumin, Protease Inhibitors and Other Products
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 36: Canada 15-Year Perspective for Plasma Fractionation
by Product - Percentage Breakdown of Value Sales for
Intravenous Immunoglobulins, Coagulation Factor Concentrates,
Albumin, Protease Inhibitors and Other Products for the Years
2012, 2020 & 2027

Table 37: Canada Current & Future Analysis for Plasma
Fractionation by End-Use - Hospitals & Clinics, Clinical
Research Laboratories and Academic Institutes - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 38: Canada Historic Review for Plasma Fractionation by
End-Use - Hospitals & Clinics, Clinical Research Laboratories
and Academic Institutes Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 39: Canada 15-Year Perspective for Plasma Fractionation
by End-Use - Percentage Breakdown of Value Sales for Hospitals &
Clinics, Clinical Research Laboratories and Academic
Institutes for the Years 2012, 2020 & 2027

JAPAN
Table 40: Japan Current & Future Analysis for Plasma
Fractionation by Product - Intravenous Immunoglobulins,
Coagulation Factor Concentrates, Albumin, Protease Inhibitors
and Other Products - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR

Table 41: Japan Historic Review for Plasma Fractionation by
Product - Intravenous Immunoglobulins, Coagulation Factor
Concentrates, Albumin, Protease Inhibitors and Other Products
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 42: Japan 15-Year Perspective for Plasma Fractionation by
Product - Percentage Breakdown of Value Sales for Intravenous
Immunoglobulins, Coagulation Factor Concentrates, Albumin,
Protease Inhibitors and Other Products for the Years 2012, 2020 &
2027

Table 43: Japan Current & Future Analysis for Plasma
Fractionation by End-Use - Hospitals & Clinics, Clinical
Research Laboratories and Academic Institutes - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 44: Japan Historic Review for Plasma Fractionation by
End-Use - Hospitals & Clinics, Clinical Research Laboratories
and Academic Institutes Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 45: Japan 15-Year Perspective for Plasma Fractionation by
End-Use - Percentage Breakdown of Value Sales for Hospitals &
Clinics, Clinical Research Laboratories and Academic Institutes
for the Years 2012, 2020 & 2027

CHINA
Table 46: China Current & Future Analysis for Plasma
Fractionation by Product - Intravenous Immunoglobulins,
Coagulation Factor Concentrates, Albumin, Protease Inhibitors
and Other Products - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR

Table 47: China Historic Review for Plasma Fractionation by
Product - Intravenous Immunoglobulins, Coagulation Factor
Concentrates, Albumin, Protease Inhibitors and Other Products
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 48: China 15-Year Perspective for Plasma Fractionation by
Product - Percentage Breakdown of Value Sales for Intravenous
Immunoglobulins, Coagulation Factor Concentrates, Albumin,
Protease Inhibitors and Other Products for the Years 2012, 2020 &
2027

Table 49: China Current & Future Analysis for Plasma
Fractionation by End-Use - Hospitals & Clinics, Clinical
Research Laboratories and Academic Institutes - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 50: China Historic Review for Plasma Fractionation by
End-Use - Hospitals & Clinics, Clinical Research Laboratories
and Academic Institutes Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 51: China 15-Year Perspective for Plasma Fractionation by
End-Use - Percentage Breakdown of Value Sales for Hospitals &
Clinics, Clinical Research Laboratories and Academic Institutes
for the Years 2012, 2020 & 2027

EUROPE
Table 52: Europe Current & Future Analysis for Plasma
Fractionation by Geographic Region - France, Germany, Italy, UK
and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2020 through 2027 and % CAGR

Table 53: Europe Historic Review for Plasma Fractionation by
Geographic Region - France, Germany, Italy, UK and Rest of
Europe Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 54: Europe 15-Year Perspective for Plasma Fractionation
by Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK and Rest of Europe Markets for Years
2012, 2020 & 2027

Table 55: Europe Current & Future Analysis for Plasma
Fractionation by Product - Intravenous Immunoglobulins,
Coagulation Factor Concentrates, Albumin, Protease Inhibitors
and Other Products - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR

Table 56: Europe Historic Review for Plasma Fractionation by
Product - Intravenous Immunoglobulins, Coagulation Factor
Concentrates, Albumin, Protease Inhibitors and Other Products
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 57: Europe 15-Year Perspective for Plasma Fractionation
by Product - Percentage Breakdown of Value Sales for
Intravenous Immunoglobulins, Coagulation Factor Concentrates,
Albumin, Protease Inhibitors and Other Products for the Years
2012, 2020 & 2027

Table 58: Europe Current & Future Analysis for Plasma
Fractionation by End-Use - Hospitals & Clinics, Clinical
Research Laboratories and Academic Institutes - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 59: Europe Historic Review for Plasma Fractionation by
End-Use - Hospitals & Clinics, Clinical Research Laboratories
and Academic Institutes Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 60: Europe 15-Year Perspective for Plasma Fractionation
by End-Use - Percentage Breakdown of Value Sales for Hospitals &
Clinics, Clinical Research Laboratories and Academic
Institutes for the Years 2012, 2020 & 2027

FRANCE
Table 61: France Current & Future Analysis for Plasma
Fractionation by Product - Intravenous Immunoglobulins,
Coagulation Factor Concentrates, Albumin, Protease Inhibitors
and Other Products - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR

Table 62: France Historic Review for Plasma Fractionation by
Product - Intravenous Immunoglobulins, Coagulation Factor
Concentrates, Albumin, Protease Inhibitors and Other Products
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 63: France 15-Year Perspective for Plasma Fractionation
by Product - Percentage Breakdown of Value Sales for
Intravenous Immunoglobulins, Coagulation Factor Concentrates,
Albumin, Protease Inhibitors and Other Products for the Years
2012, 2020 & 2027

Table 64: France Current & Future Analysis for Plasma
Fractionation by End-Use - Hospitals & Clinics, Clinical
Research Laboratories and Academic Institutes - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 65: France Historic Review for Plasma Fractionation by
End-Use - Hospitals & Clinics, Clinical Research Laboratories
and Academic Institutes Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 66: France 15-Year Perspective for Plasma Fractionation
by End-Use - Percentage Breakdown of Value Sales for Hospitals &
Clinics, Clinical Research Laboratories and Academic
Institutes for the Years 2012, 2020 & 2027

GERMANY
Table 67: Germany Current & Future Analysis for Plasma
Fractionation by Product - Intravenous Immunoglobulins,
Coagulation Factor Concentrates, Albumin, Protease Inhibitors
and Other Products - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR

Table 68: Germany Historic Review for Plasma Fractionation by
Product - Intravenous Immunoglobulins, Coagulation Factor
Concentrates, Albumin, Protease Inhibitors and Other Products
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 69: Germany 15-Year Perspective for Plasma Fractionation
by Product - Percentage Breakdown of Value Sales for
Intravenous Immunoglobulins, Coagulation Factor Concentrates,
Albumin, Protease Inhibitors and Other Products for the Years
2012, 2020 & 2027

Table 70: Germany Current & Future Analysis for Plasma
Fractionation by End-Use - Hospitals & Clinics, Clinical
Research Laboratories and Academic Institutes - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 71: Germany Historic Review for Plasma Fractionation by
End-Use - Hospitals & Clinics, Clinical Research Laboratories
and Academic Institutes Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 72: Germany 15-Year Perspective for Plasma Fractionation
by End-Use - Percentage Breakdown of Value Sales for Hospitals &
Clinics, Clinical Research Laboratories and Academic
Institutes for the Years 2012, 2020 & 2027

ITALY
Table 73: Italy Current & Future Analysis for Plasma
Fractionation by Product - Intravenous Immunoglobulins,
Coagulation Factor Concentrates, Albumin, Protease Inhibitors
and Other Products - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR

Table 74: Italy Historic Review for Plasma Fractionation by
Product - Intravenous Immunoglobulins, Coagulation Factor
Concentrates, Albumin, Protease Inhibitors and Other Products
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 75: Italy 15-Year Perspective for Plasma Fractionation by
Product - Percentage Breakdown of Value Sales for Intravenous
Immunoglobulins, Coagulation Factor Concentrates, Albumin,
Protease Inhibitors and Other Products for the Years 2012, 2020 &
2027

Table 76: Italy Current & Future Analysis for Plasma
Fractionation by End-Use - Hospitals & Clinics, Clinical
Research Laboratories and Academic Institutes - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 77: Italy Historic Review for Plasma Fractionation by
End-Use - Hospitals & Clinics, Clinical Research Laboratories
and Academic Institutes Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 78: Italy 15-Year Perspective for Plasma Fractionation by
End-Use - Percentage Breakdown of Value Sales for Hospitals &
Clinics, Clinical Research Laboratories and Academic Institutes
for the Years 2012, 2020 & 2027

UNITED KINGDOM
Table 79: UK Current & Future Analysis for Plasma Fractionation
by Product - Intravenous Immunoglobulins, Coagulation Factor
Concentrates, Albumin, Protease Inhibitors and Other Products -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 80: UK Historic Review for Plasma Fractionation by
Product - Intravenous Immunoglobulins, Coagulation Factor
Concentrates, Albumin, Protease Inhibitors and Other Products
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 81: UK 15-Year Perspective for Plasma Fractionation by
Product - Percentage Breakdown of Value Sales for Intravenous
Immunoglobulins, Coagulation Factor Concentrates, Albumin,
Protease Inhibitors and Other Products for the Years 2012, 2020 &
2027

Table 82: UK Current & Future Analysis for Plasma Fractionation
by End-Use - Hospitals & Clinics, Clinical Research
Laboratories and Academic Institutes - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 83: UK Historic Review for Plasma Fractionation by
End-Use - Hospitals & Clinics, Clinical Research Laboratories
and Academic Institutes Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 84: UK 15-Year Perspective for Plasma Fractionation by
End-Use - Percentage Breakdown of Value Sales for Hospitals &
Clinics, Clinical Research Laboratories and Academic Institutes
for the Years 2012, 2020 & 2027

REST OF EUROPE
Table 85: Rest of Europe Current & Future Analysis for Plasma
Fractionation by Product - Intravenous Immunoglobulins,
Coagulation Factor Concentrates, Albumin, Protease Inhibitors
and Other Products - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR

Table 86: Rest of Europe Historic Review for Plasma
Fractionation by Product - Intravenous Immunoglobulins,
Coagulation Factor Concentrates, Albumin, Protease Inhibitors
and Other Products Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 87: Rest of Europe 15-Year Perspective for Plasma
Fractionation by Product - Percentage Breakdown of Value Sales
for Intravenous Immunoglobulins, Coagulation Factor
Concentrates, Albumin, Protease Inhibitors and Other Products
for the Years 2012, 2020 & 2027

Table 88: Rest of Europe Current & Future Analysis for Plasma
Fractionation by End-Use - Hospitals & Clinics, Clinical
Research Laboratories and Academic Institutes - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 89: Rest of Europe Historic Review for Plasma
Fractionation by End-Use - Hospitals & Clinics, Clinical
Research Laboratories and Academic Institutes Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 90: Rest of Europe 15-Year Perspective for Plasma
Fractionation by End-Use - Percentage Breakdown of Value Sales
for Hospitals & Clinics, Clinical Research Laboratories and
Academic Institutes for the Years 2012, 2020 & 2027

ASIA-PACIFIC
Table 91: Asia-Pacific Current & Future Analysis for Plasma
Fractionation by Product - Intravenous Immunoglobulins,
Coagulation Factor Concentrates, Albumin, Protease Inhibitors
and Other Products - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR

Table 92: Asia-Pacific Historic Review for Plasma Fractionation
by Product - Intravenous Immunoglobulins, Coagulation Factor
Concentrates, Albumin, Protease Inhibitors and Other Products
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 93: Asia-Pacific 15-Year Perspective for Plasma
Fractionation by Product - Percentage Breakdown of Value Sales
for Intravenous Immunoglobulins, Coagulation Factor
Concentrates, Albumin, Protease Inhibitors and Other Products
for the Years 2012, 2020 & 2027

Table 94: Asia-Pacific Current & Future Analysis for Plasma
Fractionation by End-Use - Hospitals & Clinics, Clinical
Research Laboratories and Academic Institutes - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 95: Asia-Pacific Historic Review for Plasma Fractionation
by End-Use - Hospitals & Clinics, Clinical Research
Laboratories and Academic Institutes Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 96: Asia-Pacific 15-Year Perspective for Plasma
Fractionation by End-Use - Percentage Breakdown of Value Sales
for Hospitals & Clinics, Clinical Research Laboratories and
Academic Institutes for the Years 2012, 2020 & 2027

REST OF WORLD
Table 97: Rest of World Current & Future Analysis for Plasma
Fractionation by Product - Intravenous Immunoglobulins,
Coagulation Factor Concentrates, Albumin, Protease Inhibitors
and Other Products - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR

Table 98: Rest of World Historic Review for Plasma
Fractionation by Product - Intravenous Immunoglobulins,
Coagulation Factor Concentrates, Albumin, Protease Inhibitors
and Other Products Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 99: Rest of World 15-Year Perspective for Plasma
Fractionation by Product - Percentage Breakdown of Value Sales
for Intravenous Immunoglobulins, Coagulation Factor
Concentrates, Albumin, Protease Inhibitors and Other Products
for the Years 2012, 2020 & 2027

Table 100: Rest of World Current & Future Analysis for Plasma
Fractionation by End-Use - Hospitals & Clinics, Clinical
Research Laboratories and Academic Institutes - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 101: Rest of World Historic Review for Plasma
Fractionation by End-Use - Hospitals & Clinics, Clinical
Research Laboratories and Academic Institutes Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 102: Rest of World 15-Year Perspective for Plasma
Fractionation by End-Use - Percentage Breakdown of Value Sales
for Hospitals & Clinics, Clinical Research Laboratories and
Academic Institutes for the Years 2012, 2020 & 2027

IV. COMPETITION
Total Companies Profiled: 47